Fernando Alonso exclusive: F1’s returning champion talks Renault 2021 move

first_img Simon Lazenby caught up with Fernando Alonso ahead of his return to Formula 1 with Renault next season “Honestly, I expect to be straight up to speed,” stated Alonso. “But I’m aware of the challenge that maybe I face in the first couple of races. Not only on pure speed, but also on procedures, steering wheel commands, things that are new for me and could take some time. I’m aware that I could struggle a little bit.“But I want to think that it will not happen.”‘Stopwatch will decide when I stop, not third title’Alonso has signed an initial two-year contract with Renault, meaning he is set to race until at least the age of 41. But, when asked if he will keep racing until he secures what feels like a long-overdue third title, he said his competitiveness will be the deciding factor, not championships.“I don’t think I will target a certain result before I stop,” he told Lazenby. “I think in motorsport, the stopwatch tells you when it is time to stop, not the age. I hope the stopwatch is on my side in the next coming years.” But he also knows he needs more track time, adding: “When you go out of the sport for two years and then you drive a Formula 1 car again, everything surprises you like the first time. I need those laps now.“The simulator is good until a certain point, but then you need the physical effort of the car, the G-forces, the training of the neck. I need as many laps as possible.”First few races could be a ‘struggle’… but will they be?That’s not to say Alonso expects to be rusty when he does get started officially next year – even though he acknowledges that it could be a ‘struggle’. – Advertisement – – Advertisement – – Advertisement – Talks between Renault and Alonso ramped up after Daniel Ricciardo’s surprise confirmation, back in May, that he would be leaving for McLaren, before a reunion between the French team and the driver who claimed their last two Drivers’ Championships in 2005 and 2006 was announced in July.With Renault fifth in last year’s constructors’ standings, they didn’t appear to have what Alonso has always stressed would be key for him making an F1 comeback – a winning package – but he insisted to Simon that, with new rules on the way in 2022, they are the perfect fit.“[They were the preferred choice] for two reasons,” he continued. “One, in terms of expectations and building something from the midfield to the top, it was very attractive, very appealing. And secondly because I know everyone in this team. I know the passion for racing. It’s the third time I come here and I knew I would feel at home here.”Renault are leading the midfield this season, currently third with four races to go, so the signs for Alonso – a man who has famously not had luck on his side with career decisions in the past – are promising. They will be known as Alpine next season and, presumably, a convenient return to a blue livery.Renault car ‘amazing’ but he ‘needs laps’Alonso stepped up his preparations for 2021 with a filming day in Barcelona last month, completing 21 laps in the team’s current car.“It was amazing,” he said. “It was quite an experience.” 5:17

Study shows few serious problems among smallpox vaccinees

first_imgDec 14, 2005 (CIDRAP News) – Exactly 100 of about 38,000 civilians who received smallpox shots in a federal program in 2003 suffered serious adverse events afterward, signaling that the program successfully screened out most people at risk for complications, according to a recent report.The safety monitoring system “achieved its goal of safe administration of smallpox vaccine among a limited number of DHHS [Department of Health and Human Services] volunteers through successful exclusion of at-risk individuals and rapid detection of unexpected adverse events,” says the report, published in the Dec 7 Journal of the American Medical Association.The authors, with the Centers for Disease Control and Prevention (CDC), analyzed adverse events reported as a result of the smallpox vaccination program from January through October of 2003. HHS launched the program for healthcare and emergency response workers out of concern about the possibility of a terrorist release of smallpox virus. The report’s first author is Christine G. Casey, MD, of the CDC’s National Immunization Program.Authorities originally hoped to vaccinate as many as 500,000 health workers, but only 37,901 received shots by the end of October 2003. Hospital and public health workers constituted 95% of those, with law enforcement and firefighters making up most of the rest, the report says. Most of the vaccinees (64%) were women, and more than 75% of them were between 40 and 64 years old and had received a smallpox shot before.The Vaccine Adverse Event Reporting System (VAERS) received 822 adverse-event reports related to the vaccinations, the report says. Of these, 100 were classified as serious events, for a rate of 26.4 per 10,000 vaccinees.Of the 100 serious events, 85 involved hospitalization or prolongation of hospitalization. Two people suffered permanent disability, and 10 experienced a life-threatening illness. The serious events included 21 classified as myopericarditis and 10 classified as ischemic events that were not expected on the basis of patient histories. Those 10 included six myocardial infarctions, two of which were fatal, and four cases of new or increased angina. Two cases of dilated cardiomyopathy occurring 2 to 3 months after vaccination were also reported.As a result of cardiac adverse events in both civilian and military smallpox vaccinees, the CDC issued a Health Alert Notice on Mar 26, 2003, that described the events and recommended deferring vaccination for at-risk people. None of the 10 ischemic cardiac events in vaccinees occurred after the alert notice triggered cardiac screening of potential vacccinees, the report says.The authors note that US military personnel recently vaccinated against smallpox have had a significantly increased rate of myocarditis, compared with unvaccinated military members. However, the report says the rate of ischemic cardiac events in civilian vaccinees does not appear to exceed the rate in a comparable unvaccinated population.”Whether smallpox vaccination is causally associated with ischemic events remains uncertain,” the authors write.Two cases of generalized vaccinia and one case of postvaccinial encephalitis were reported in the program. But there were no cases of transmission of vaccinia (the vaccine virus) to others and no severe reactions requiring treatment with vaccinia immune globulin.Among the 722 “nonserious” adverse events reported, the most common signs and symptoms were fever, 18.9%; rash, 18.4%; pain, 16.0%; headache, 15.2%; fatigue, 13.5%; and pruritus, 13.4%. Compared with those reporting nonserious events, people reporting serious events were more likely to be older than 40 (81% versus 64%).People who had been vaccinated previously were slightly overrepresented among the vaccinees with serious adverse events, the authors found. They say this is not surprising, since the revaccinees were older than the primary vaccinees and may have had a higher risk of adverse events because of age-related underlying chronic disease.The rates of expected, preventable, and noncardiac adverse events in the civilian vaccinees were about the same as rates in the much larger military vaccination program, the authors found.Casey CG, Iskander JK, Roper MH, et al. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA 2005 Dec 7;294(21):2734-43 [Abstract]See also:Safety summary for Department of Defense smallpox vaccination programhttp://www.smallpox.mil/event/SPSafetySum.asplast_img read more